12. Segments

9 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segments

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Nine Months Ended December 31,
	2016			2015
Revenues:
Aethlon	$	392,073		$	681,907
ESI		–			–
Total Revenues	$	392,073		$	681,907
Operating Losses:
Aethlon	$	(4,478,631	)	$	(2,916,018	)
ESI		(115,443	)		(382,442	)
Total Operating Loss	$	(4,594,074	)	$	(3,298,460	)
Net Losses:
Aethlon	$	(5,497,978	)	$	(3,318,855	)
ESI		(115,443	)		(382,442	)
Net Loss Before Non-Controlling Interests	$	(5,613,421	)	$	(3,701,297	)
Cash:
Aethlon	$	625,531		$	3,221,006
ESI		3,084			29,891
Total Cash	$	628,615		$	3,250,897
Total Assets:
Aethlon	$	752,578		$	3,514,098
ESI		37,019			78,765
Total Assets	$	789,597		$	3,592,863
Capital Expenditures:
Aethlon	$	2,961		$	9,307
ESI		–			–
Capital Expenditures	$	2,961		$	9,307
Depreciation and Amortization:
Aethlon	$	16,322		$	13,902
ESI		10,043			14,685
Total Depreciation and Amortization	$	26,365		$	28,587
Interest Expense:
Aethlon	$	(115,308	)	$	(402,837	)
ESI		–			–
Total Interest Expense	$	(115,308	)	$	(402,837	)